Rivaroxaban Kit
Product Images NDC 62332-240

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Rivaroxaban (NDC 62332-240). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30 Tablets (Rivaroxaban 10mg)

Rivaroxaban 10 mg Tablets, USP oral film-coated tablets by Alembic Pharmaceuticals Inc. The label shows storage instructions at 25°C (77°F) with permitted excursions, and mentions the tablets are dispensed with a medication guide. The NDC number 62332-346-30 and package quantity of 30 tablets are also visible. Manufacturer details include Alembic Pharmaceuticals Limited, India, and Alembic Pharmaceuticals, Inc., USA.*

FDA Label Image

42 Tablets And 9 Tablets (Rivaroxaban 1520mg)

Packaging label for Rivaroxaban Tablets, USP starter pack containing 42 film-coated tablets of 15 mg (dosage for days 1-21) and 9 tablets of 20 mg (dosage for days 22-30). The label includes dosage instructions, storage conditions, and manufacturer information for Alembic Pharmaceuticals Inc.*

FDA Label Image

30 Tablets (Rivaroxaban 15mg)

Rivaroxaban Tablets, USP 15 mg label from Alembic Pharmaceuticals Inc. The label indicates the active ingredient rivaroxaban USP 15 mg per tablet, with storage instructions and manufacturer details. Package contains 30 film-coated tablets, with a barcode and dosage instructions summarizing to consult the medication guide. The label includes the NDC number 62332-347-30 and notes that the medication is Rx only.*

FDA Label Image

60 Tablets (Rivaroxaban 2 5mg)

Label for Rivaroxaban Tablets USP 2.5 mg, film-coated oral tablets, manufactured by Alembic Pharmaceuticals Inc. The label shows the strength (2.5 mg), quantity (60 tablets), storage instructions, and barcode. It includes directions to dispense the Medication Guide and notes the Rx only status. The label also specifies manufacturing origin in Gujarat, India and Bedminster, NJ, USA.*

FDA Label Image

30 Tablets (Rivaroxaban 20mg)

Label for Rivaroxaban Tablets, USP 20 mg, film-coated tablets in a 30-tablet package. The label shows the NDC 62332-348-30 and instructs storage at 25°C (77°F) with permitted excursions. Manufactured by Alembic Pharmaceuticals Limited, Gujarat, India, and Alembic Pharmaceuticals, Inc., New Jersey, USA. Includes a barcode and dispenser instructions.*

FDA Label Image

Rivaroxaban-fig-1 (Rivaroxaban Fig 1)

A forest plot chart comparing hazard ratios and 95% confidence intervals between Rivaroxaban and Warfarin across various patient subgroups. The chart includes data categorized by prior VKA use, age, gender, weight, prior stroke/TIA, diabetes status, CHADS2 score, creatinine clearance levels, geographic region, and ASA randomization. Each subgroup is represented with corresponding event rates and confidence intervals favoring either Rivaroxaban or Warfarin.*

FDA Label Image

Rivaroxaban-fig-2.jpg (Rivaroxaban Fig 2)

A chart showing the fold change and 90% confidence interval of pharmacokinetic (PK) parameters Cmax and AUC for rivaroxaban under various conditions. The chart compares populations with end-stage renal disease, different degrees of renal impairment, age groups, body weight categories, and hepatic impairment relative to normal controls.*

FDA Label Image

Rivaroxaban-fig-3.jpg (Rivaroxaban Fig 3)

A forest plot chart showing fold change and 90% confidence intervals for pharmacokinetic parameters Cmax and AUC of rivaroxaban when combined with various interacting drugs. The chart categorizes drugs as combined P-gp and strong or moderate CYP3A inhibitors, combined P-gp and strong CYP3A inducer, and other drugs, and displays changes relative to rivaroxaban alone along a horizontal axis from 0.25 to 4-fold.*

FDA Label Image

Rivaroxaban-fig5.jpg (Rivaroxaban Fig5)

A forest plot comparing hazard ratios and 95% confidence intervals for Rivaroxaban versus Warfarin across various patient subgroups, including prior Warfarin/VKA use, age, gender, weight, prior stroke/TIA, diabetic status, CHADS2 score, creatinine clearance, geographic region, and ASA use. The plot visually displays treatment effect and variability for each subgroup.*

FDA Label Image

Rivaroxaban-figure10.jpg (Rivaroxaban Figure10)

A line graph showing the cumulative incidence rate (%) over days from randomization up to 1095 (three years) comparing Rivaroxaban Tablets versus Placebo. The graph shows hazard ratio with 95% confidence interval (0.74, 0.65 to 0.86). A table below the graph lists the number of subjects at risk over time for both groups.*

FDA Label Image

Rivaroxaban-figure11.jpg (Rivaroxaban Figure11)

A line graph comparing the cumulative incidence rate (%) over days from randomization for Rivaroxaban tablets versus placebo. The x-axis shows days up to 1095, and the y-axis shows the cumulative incidence rate percentage. Two lines represent treatment groups: a solid line for Rivaroxaban tablets and a dashed line for placebo, with Rivaroxaban showing a consistently lower incidence rate. The graph includes a table of subjects at risk over time and a hazard ratio with 95% confidence interval comparing Rivaroxaban to placebo.*

FDA Label Image

Rivaroxaban-figure12.jpg (Rivaroxaban Figure12)

A forest plot comparing the efficacy of Rivaroxaban tablets versus placebo across various subgroups, showing hazard ratios (HR) with 95% confidence intervals (CI). The plot includes categories such as age, sex, weight, eGFR, diabetes status, coronary artery disease, randomization stratum, clopidogrel use, history of revascularization, and critical limb ischemia. The horizontal axis ranges from 0.5 to 2, indicating comparative favorability between Rivaroxaban and placebo.*

FDA Label Image

Rivaroxaban-figure4.jpg (Rivaroxaban Figure4)

A line graph comparing the cumulative event rates percentage over days from randomization for Rivaroxaban Tablets and Warfarin. The graph shows two curves: a solid line for Rivaroxaban Tablets and a dashed line for Warfarin, with the cumulative event rate increasing over approximately 900 days. A hazard ratio (HR) with 95% confidence interval is displayed on the graph.*

FDA Label Image

Rivaroxaban-figure6.jpg (Rivaroxaban Figure6)

This image is a Kaplan-Meier curve comparing the cumulative event rates (%) over days from randomization between Enoxaparin/VKA (dashed line) and Rivaroxaban Tablets (solid line). It shows event rate progression over approximately 360 days and includes a hazard ratio (HR) with 95% confidence interval (0.68 [0.44, 1.04]).*

FDA Label Image

Rivaroxaban-figure7.jpg (Rivaroxaban Figure7)

A line graph comparing the cumulative event rate percentage over days from randomization between Enoxaparin/VKA (dashed line) and Rivaroxaban Tablets (solid line). The x-axis represents days up to 360, and the y-axis shows cumulative event rate from 0 to 4%. A hazard ratio with 95% confidence interval is provided in the lower right corner.*

FDA Label Image

Rivaroxaban-figure8.jpg (Rivaroxaban Figure8)

A cumulative event rate graph comparing Rivaroxaban Tablets and Aspirin over 367 days from randomization. The solid line represents Rivaroxaban Tablets showing a lower event rate, while the dashed line represents Aspirin with a higher cumulative event rate. Below the graph, the number of subjects at risk per time point for both groups is displayed. The hazard ratio with 95% confidence interval (0.26, 0.14 to 0.47) is indicated on the graph.*

FDA Label Image

Rivaroxaban-figure9.jpg (Rivaroxaban Figure9)

A forest plot displaying the efficacy outcomes of Rivaroxaban tablets compared to placebo across various subgroups, including age, sex, region, weight, kidney function (eGFR), medical history, and baseline diabetes status. The plot shows hazard ratios (HR) with 95% confidence intervals, illustrating the relative risk benefit favoring rivaroxaban or placebo for each subgroup.*

FDA Label Image

Rivaroxaban-str (Rivaroxaban Structure)

Chemical structure of rivaroxaban, showing its molecular composition including rings, nitrogen, oxygen, sulfur, and chlorine atoms as part of its distinctive anticoagulant compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.